ImmunityBio reported durable complete responses of up to 15 months in recipients of its off‑the‑shelf CAR‑NK cell therapy, citing cases across ongoing trials and highlighting the potential of allogeneic NK platforms for hematologic malignancies. The company also released early Phase‑1 data from QUILT‑106 in rare lymphomas, noting encouraging signals in a small patient cohort. ImmunityBio’s statements named specific durable responses and emphasized the logistical advantages of off‑the‑shelf cell products, which can be administered without patient‑derived manufacturing. The company plans continued enrollment and follow‑up to confirm durability and safety as it advances development.